Skip to main content

Table 3 NanoString counts of individual genes of significance (p values < 0.05), analyzed from tumor core biopsy samples prior to study treatment. Fold change is PR vs PD (baseline)

From: An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

Gene name

PR

PD

Fold change

Affected pathway

CALML5

143.27

2255.68

− 15.74

MAPK

MMP7

453.82

5649.84

− 12.45

WNT

BRCA1

57.16

275.57

− 4.82

DNA damage repair, PI3K

PLA2G3

196.18

41.35

4.74

MAPK

CRYAB

568.51

2587.04

− 4.55

DNA damage repair

COL11A1

65.8

294.98

− 4.48

PI3K

CKB

100.47

438.12

− 4.36

DNA

LFNG

722.24

175.07

4.13

Notch

RASGRF1

41.19

156.18

− 3.79

MAPK

PIK3R3

2009.36

558.36

3.6

JAK/STAT, MAPK, PI3K

SOCS1

362.96

104.85

3.46

JAK/STAT

GJB2

395.9

125.75

3.15

DNA damage repair

PTCH1

23.77

72.6

− 3.05

Hedgehog

STAT1

5748.18

1940.41

2.96

JAK/STAT

COL27A1

81.66

209.94

− 2.57

PI3K

SOCS2

498.48

197

2.53

JAK/STAT

FGFR2

133.74

333.34

− 2.49

MAPK, PI3K

NOTCH1

194.05

439.53

− 2.27

Notch

HGF

181.46

81.94

2.21

MAPK, PI3K